Impact of cancer on mortality and severity of corona virus disease 2019
A protocol for systematic review and meta-analysis

Yi Zhang, MD, Hao Han, MD, Yunling Tian, MD, Jing Dong, MD, Yage Yu, MD, Yingying Kang, MD, Lina Xing, MD, Rongna Lian, BS, Ruinian Zhang, BS, Dairong Xie, BS

Abstract
Background: Cancer patients are in a state of systemic immunosuppression and are considered a highly vulnerable population in the Corona Virus Disease 2019 (COVID-19) epidemic. However, the relationship between cancer and the severity and mortality of patients with COVID-19 remains unclear. This study aims to evaluate whether cancer patients with COVID-19 may be at an increased risk of severe illness and mortality.

Methods: We will perform comprehensive searches in PubMed, EMBASE.com, Web of Science, and the Cochrane Central Register of Controlled Trials to identify studies providing prevalence of cancer between patients with severe and non-severe illness or between non-survivors and survivors. We will use the Newcastle-Ottawa quality assessment scale to assess the quality of included studies. We will conduct pairwise meta-analyses to compute the odds ratio and 95% confidence interval using the Mantel Haenszel method with the random-effects model. The statistical heterogeneity will be assessed using the I^2 statistic. Subgroup analyses, sensitivity analyses, and meta-regression analyses will be performed to explore the sources of heterogeneity.

Results: The results of this study will be published in a peer-reviewed journal.

Conclusion: Our meta-analysis will systematically evaluate the association between cancer and the severity and mortality of patients with COVID-19. This study will provide evidence to help determine whether cancer patients should be provided with special precautions and advised to use stronger personal protection.

INPLASY registration number: INPLASY202000003.

Abbreviation: COVID-19 = corona virus disease 2019.

Keywords: corona virus disease 2019, meta-analysis, mortality, neoplasms, severity

1. Introduction
As of September 18, 2020, a total of 30,055,710 laboratory-confirmed Coronavirus disease 2019 (COVID-19) cases were reported worldwide, with 943,433 deaths (mortality rate: 3.1%).[1] Several studies have evaluated the impact of comorbidities on patients infected with COVID-19, which showed that comorbidities in COVID-19 patients are associated with poor prognosis, including cerebrovascular disease, hypertension,
obesity, chronic obstructive pulmonary disease, stroke, diabetes, cardiovascular disease, and kidney injury.[2–4]

The development of cancer is usually related to a blunted immune status,[9,10] and anti-cancer treatments (such as chemotherapy) can also put cancer patients in an immunosuppressive state.[11] Therefore, immunodeficiency may make cancer patients susceptible to COVID-19. Primary studies showed that cancer patients infected with COVID-19 had a higher risk of serious clinical events and death than those without cancer.[12,13]

A previous meta-analysis assessed the relationship between cancer and COVID-19 prognosis and found that there was no correlation between cancer and the severity of patients with COVID-19.[14] However, another 2 meta-analyses suggested that the presence of cancer in COVID-19 patients increased the risk of developing serious complications.[15,16] These meta-analyses did not reach consistent results. Furthermore, existing meta-analyses are limited by the small sample size and the conclusions are inconclusive. Therefore, a comprehensive meta-analysis is urgently needed to answer clinical questions. The primary objective of this study is to investigate the association between cancer and COVID-19 mortality.

2. Methods

We will report this systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.[17] This study protocol has been registered in the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY, INPLASY202090093, doi: 10.37766/inplasy2020.9.0093).

2.1. Eligibility criteria

We will include studies that meet the following criteria:

(1) patients have a laboratory-confirmed diagnosis of COVID-19;

(2) provided the prevalence of cancer between COVID-19 patients with severe and non-severe illness or between non-survivors and survivors;

(3) with a sample size of larger than 10 patients;

(4) published in Chinese or English.

The following studies will be excluded:

(1) studies did not report data related to cancer patients;

(2) studies focused on only suspected cases or suspected cases and confirmed cases;

(3) review articles, protocols, guidelines, consensus, comments, abstracts, letters, and editorials.

2.2. Information sources and search strategy

We will perform comprehensive searches in PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to September 30, 2020. We will use search terms include the following words: “severe acute respiratory syndrome coronavirus 2,” “SARS-CoV-2,” “coronavirus disease-19,” “COVID-19,” “novel coronavirus,” “new coronavirus,” “2019-nCoV,” “novel coronavirus,” “nCoV-2019,” “novel coronavirus pneumonia,” “2019 novel coronavirus,” “coronavirus disease 2019,” “neoplasms,” “neoplasia,” “tumor,” “tumour,” “cancer,” “malignancy,” “clinical characteristic,” “clinical feature,” “risk factor,” “prognosis,” and “comorbidities.” The search strategy of PubMed is presented in Table 1. Reference lists of eligible studies and relevant systematic reviews will be also manually searched for potentially eligible studies.

2.3. Study selection process

We will import the retrieved records into EndNote X8 (Thomson Reuters (Scientific) LLC Philadelphia, PA) software for management. Two authors independently will screen the titles and abstracts of the records to determine if they meet the inclusion criteria. Then, the same 2 authors will retrieve the full text of all potentially eligible studies and assess the eligibility of each study according to the inclusion criteria. Regarding multiple studies from the same teams or studies with samples from the same settings, we will evaluate the time frame and detailed data of the study. For studies with overlapping data, we will include the study with a larger sample size. Conflicts will be resolved by discussions with a third reviewer.

| Table 1 | Search strategy of PubMed. |
|---------|--------------------------|
| #1      | “COVID-19”[Supplementary Concept] OR “severe acute respiratory syndrome coronavirus 2”[Supplementary Concept] |
| #2      | COVID-19[Title/Abstract] OR COVID-19[Title/Abstract] OR 2019 novel coronavirus[Title/Abstract] OR 2019-nCoV[Title/Abstract] OR coronavirus disease 2019[Title/Abstract] OR coronavius disease-19[Title/Abstract] OR new coronavirus[Title/Abstract] OR novel coronavirus[Title/Abstract] OR nCoV-2019[Title/Abstract] OR novel coronavirus pneumonia[Title/Abstract] OR “severe acute respiratory syndrome coronavirus 2”[Title/Abstract] OR SARS-CoV-2[Title/Abstract] |
| #3      | #1 OR #2 |
| #4      | “Neoplasms”[Mesh] |
| #5      | Neoplasms[Title/Abstract] OR Neoplasm[Title/Abstract] OR Neoplasia[Title/Abstract] OR Neoplasms[Title/Abstract] OR Neoplasia[Title/Abstract] OR Tumors[Title/Abstract] OR Tumor[Title/Abstract] OR Tumours[Title/Abstract] OR Tumour[Title/Abstract] OR Cancer[Title/Abstract] OR Cancers[Title/Abstract] OR Malignancy[Title/Abstract] OR Malignancies[Title/Abstract] |
| #6      | #4 OR #5 |
| #7      | clinical characteristic[Title/Abstract] OR clinical characteristics[Title/Abstract] OR clinical feature[Title/Abstract] OR clinical features[Title/Abstract] OR risk factor[Title/Abstract] OR risk factors[Title/Abstract] OR prognosis[Title/Abstract] OR comorbidity[Title/Abstract] OR comorbidities[Title/Abstract] |
| #8      | #6 OR #7 |
| #9      | #3 AND #8 |

COVID-19 = coronavirus disease 2019.
We plan to conduct subgroup analyses of the outcomes between different countries. Sensitivity analyses will be conducted by excluding studies with high risk of bias to assess the stability of results. We will also perform univariate meta-regression analyses to assess if either the outcomes or the heterogeneity is associated with the publication languages and number of centers of the study conducted.

2.8. Publication bias
The funnel plot and Egger test will be adopted to detect the publication bias for outcomes with studies no fewer than ten.

2.9. Certainty of evidence
The certainty of evidence for each meta-analysis will be evaluated using the Grading of Recommendations Assessment, Development, and Evaluation framework, which rated the quality considering 5 criteria: risk of bias, inconsistency, imprecision, indirectness, and publication bias.[23-25] The quality of evidence will be rated as high, moderate, low, or very low and the results will be presented in the Summary of Findings table.

3. Results

3.1. General characteristics of initially included studies
We conducted preliminary searches and included 5 studies[26-30] to conduct a pilot analysis. All included studies were from China and published in English. The sample size per study ranged from 191 to 1590 and the total sample size was 2619. The detailed characteristics are summarized in Table 2.

3.2. Association between cancer and COVID-19 mortality
Five studies[26-30] involving 2619 patients provided cancer prevalence with comparison between dead and surviving COVID-19 patients. The meta-analysis revealed that cancer was associated with a significantly enhanced risk of death (odds ratio \(= 2.63, 95\% \) confidence interval: 1.14 to 6.06, \( P = .023, I^2 = 26.4\% \)) (Fig. 1).

4. Discussion
Cancer patients are in a state of systemic immunosuppression and are considered a highly vulnerable population in the COVID-19 epidemic.[11,12] Our meta-analysis will systematically evaluate the association between cancer and the severity and mortality of patients with COVID-19. Our study will provide evidence to help determine whether cancer patients should be provided with special precautions and advised to use stronger personal protection. We hope the results of our meta-analysis can also
provide the latest references for the development of new guidelines.

**Author contributions**

YZ, HH, YLT, JD, YGY, YYK, LNX, RNL, RNZ, and DRX planned and designed the research. YZ, JD, YGY, YYK, LNX, RNL, RNZ, and DRX tested the feasibility of the study. HH and YLT provided methodological advice and revised the manuscript. YZ and HH wrote the manuscript. All authors approved the final version of the manuscript.

**Conceptualization:** Yi Zhang, Hao Han.

**Formal analysis:** Yi Zhang, Yunling Tian.

**Funding acquisition:** Yi Zhang.

**Investigation:** Yunling Tian, Jing Dong, Yage Yu, Yingying Kang, Rongna Lian, Ruinian Zhang, Dairong Xie.

**Methodology:** Yi Zhang, Jing Dong.

**Project administration:** Yi Zhang.

**Resources:** Yi Zhang, Yunling Tian, Jing Dong, Yage Yu, Yingying Kang, Lina Xing.

**Supervision:** Hao Han.

**Visualization:** Yunling Tian, Jing Dong, Yage Yu, Lina Xing, Rongna Lian, Ruinian Zhang, Dairong Xie.

**Writing – original draft:** Yi Zhang, Hao Han.

**Writing – review & editing:** Yi Zhang, Hao Han.

**References**

[1] World Health Organization. Coronavirus disease (COVID-2019) situation reports. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/wou-18-september-2020-cleared.pdf?sfvrsn=be6111c8_2.

[2] Roncon L, Zain M, Rigatelli G, et al. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol 2020;127:104354.

[3] Hu Y, Sun J, Dai Z, et al. Prevalence and severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Virol 2020;127:104371.

[4] Fridman S, Bullrich MB, Jimenez-Ruiz A, et al. Stroke Risk, phenotypes, and death in COVID-19: systematic review and newly reported cases. Neurology 2020.

[5] Chang TH, Chou CC, Chang LY. Effect of obesity and body mass index on coronavirus disease 2019 severity: a systematic review and meta-analysis. Obes Rev 2020;21:e13089.

[6] Siepmann T, Sedghi A, Simon E, et al. Increased risk of acute stroke among patients with severe COVID-19: a multicenter study and meta-analysis. Eur J Neurol 2020;doi: 10.1111/ene.14535.

[7] Peres KC, Riera R, Martimbianco ALC, et al. Body mass index and prognosis of COVID-19 infection: a systematic review. Front Endocrinol 2020;11:562.

[8] Cheruiyot I, Henry B, Lippi G, et al. Acute kidney injury is associated with worse prognosis in COVID-19 patients: a systematic review and meta-analysis. Acta Biomed 2020;91:e2020029.

[9] Schreiber RD, Old LJ, Smyth MJ. Cancer immunodediting: integrating immunity’s roles in cancer suppression and promotion. Science (New York, NY) 2011;331:1565–70.
[10] Xia Y, Jin R, Zhao J, et al. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020;21:e180.
[11] Yang S, Zhang Y, Cai J, et al. Clinical characteristics of COVID-19 after gynecologic oncology surgery in three women: a retrospective review of medical records. Oncologist 2020;25:e982–5.
[12] Liang WH, Guan WJ, Chen RC, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335–7.
[13] Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31:894–901.
[14] Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging 2020;12:6049–57.
[15] ElGohary GM, Hashmi S, Styczynski J, et al. The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 2020;doi:10.1016/j.hemonc.2020.07.005.
[16] Salunke AA, Nandy K, Pathak SK, et al. Impact of COVID-19 in cancer patients on severity of disease and fatal outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr 2020;14:1431–7.
[17] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed) 2009;339:b2535.
[18] Henry BM, de Oliveira MHS, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58:1021–8.
[19] Lippi G, Wong J, Henry BM. Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med 2020;130:304–9.
[20] Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses, 2012. Available at: http://wwwohric.ca/programs/cliICAL_epidemiology/oxfordasp.
[21] Zum M, Rigatelli G, Zuliani G, et al. Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis. J Infect 2020;81:84–6.
[22] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 2003;327:557–60.
[23] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed) 2008;336:924–6.
[24] Yao L, Sun R, Chen YL, et al. The quality of evidence in Chinese meta-analyses needs to be improved. J Clin Epidemiol 2016;74:73–9.
[25] Norris SL, Meerpohl JJ, Akl EA, et al. The skills and experience of GRADE methodologists can be assessed with a simple tool. J Clin Epidemiol 2016;79:150–8.
[26] Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ (Clinical research ed) 2020;368:m1091.
[27] Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chinese Med J 2020;133:1261–7.
[28] Guan WJ, Liang WH, Zhao Y, et al. Comorbidities and its impact on 1590 patients with Covid-19 in China: a Nationwide analysis. Eur Respir J 2020;55:2000247.
[29] Wang L, He W, Yu X, et al. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 2020;80:6:39–45.
[30] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) 2020;395:1054–62.